In yesterday’s Wall Street session, Evolent Health Inc. (NYSE:EVH) shares traded at $29.35, down -2.65% from the previous session.
As of this writing, 10 analysts cover Evolent Health Inc. (NYSE:EVH). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $63.00 and a low of $36.00, we find $47.00. Given the previous closing price of $30.15, this indicates a potential upside of 55.89 percent. EVH stock price is now -7.35% away from the 50-day moving average and -5.42% away from the 200-day moving average. The market capitalization of the company currently stands at $3.24B.
There are 1 analysts who have given it a hold rating, whereas 9 have given it a buy rating. Brokers who have rated the stock have averaged $47.22 as their price target over the next twelve months.
With the price target of $40, Stephens recently initiated with Overweight rating for Evolent Health Inc. (NYSE: EVH).
In other news, Blackley Seth, Chief Executive Officer sold 33,011 shares of the company’s stock on Jun 28. The stock was sold for $1,016,022 at an average price of $30.78. Upon completion of the transaction, the Chief Executive Officer now directly owns 783,011 shares in the company, valued at $22.98 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 16, Chief Executive Officer Blackley Seth sold 2,098 shares of the business’s stock. A total of $63,276 was realized by selling the stock at an average price of $30.16. This leaves the insider owning 783,011 shares of the company worth $22.98 million. Insiders disposed of 1,818,264 shares of company stock worth roughly $53.37 million over the past 1 year. A total of 1.70% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in EVH stock. A new stake in Evolent Health Inc. shares was purchased by IRON TRIANGLE PARTNERS LP during the first quarter worth $29,362,000. TPG GP A, LLC invested $22,398,000 in shares of EVH during the first quarter. In the first quarter, ADAGE CAPITAL PARTNERS GP, L.L.C. acquired a new stake in Evolent Health Inc. valued at approximately $12,010,000. REDWOOD INVESTMENTS, LLC acquired a new stake in EVH for approximately $9,550,000. LISANTI CAPITAL GROWTH, LLC purchased a new stake in EVH valued at around $9,379,000 in the second quarter. In total, there are 329 active investors with 96.80% ownership of the company’s stock.
Tuesday morning saw Evolent Health Inc. (NYSE: EVH) opened at $30.20. During the past 12 months, Evolent Health Inc. has had a low of $21.83 and a high of $39.78. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 1.00, and a quick ratio of 1.00. The fifty day moving average price for EVH is $31.55 and a two-hundred day moving average price translates $30.99 for the stock.
The latest earnings results from Evolent Health Inc. (NYSE: EVH) was released for Mar, 2023. The net profit margin was -2.70% and return on equity was -4.60% for EVH. The company reported revenue of $427.69 million for the quarter, compared to $297.06 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 43.98 percent. For the current quarter, analysts expect EVH to generate $460.7M in revenue.
Evolent Health Inc.(EVH) Company Profile
Evolent Health, Inc., a healthcare company, through its subsidiary, Evolent Health LLC, offers clinical and administrative solutions to payers and providers in the United States. The company operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management. It offers financial and administrative management services, such as health plan services, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients. The Clinical Solutions segment offers specialty care management services support a range of specialty care delivery stakeholders during their transition from fee-for-service to value-based care, independent of their stage of maturation and specific market dynamics in oncology, cardiology, and musculoskeletal markets; physician-oriented total cost of care solutions; and holistic total cost of care improvement. The company was founded in 2011 and is headquartered in Arlington, Virginia.
